Latest revenue
$0
as of 2025-09-30
Latest net income
$-285.6K
as of 2025-09-30
Net margin
—
as of 2025-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $14.2M
- Enterprise value
- $14.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.21
- 52-wk low
- $0.04
- Beta
- —
- Shares out
- 260.4M
5-year trend
What this company does
United Health Products makes CelluSTAT, a cotton-derived hemostatic gauze that controls bleeding and absorbs wound drainage. The company generates minimal revenue today, having paused commercial activities to pursue FDA Class III Premarket Approval for use in human surgery, where premium pricing and limited competition exist. UHP is mired in an FDA Warning Letter over violations in its 2018-19 clinical trial and is now pursuing a partner-sponsored study while funding operations through a discounted convertible note and equity line with Alumni Capital.
Generated from UEEC's filing dated 2026-04-15
Key risks
- FDA Warning Letter (March 2025) cited 5 clinical study violations including failing to file IDE and modifying FDA correspondence shown to IRB.
- PMA approval delayed indefinitely: FDA requires new pivotal IDE study in intestinal/thoracic procedures plus GCP audit not completing until July 2026.
- Dilution risk: $4M Alumni AMPA at VWAP discount plus convertible note at $0.06039 and warrants priced well below typical capitalization.
Generated from UEEC's filing dated 2026-04-15
Profitability
Gross margin
50.3%
12.7%Operating margin
-7472.1%
100.0%Net margin
-4500.0%
100.0%Return on equity
109.2%
33.4%Return on assets
-842.9%
13.7%Leverage
Debt / equity
-1.13×
1.7%Long-term debt / equity
0.00×
100.0%Debt / assets
871.7%
13.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | $0 | — | $-536.9K | +34.0% | — |
Q3 2025 2025-09-30 | $0 | — | $-285.6K | +6.0% | — |
Q2 2025 2025-06-30 | $0 | — | $-315.2K | +27.0% | — |
Q1 2025 2025-03-31 | $0 | — | $-1.5M | -238.9% | — |
Q4 2024 2024-12-31 | $0 | — | $-814.1K | — | — |
Q3 2024 2024-09-30 | $0 | — | $-303.7K | +37.5% | — |
Q2 2024 2024-06-30 | $0 | — | $-432.0K | +17.4% | — |
Q1 2024 2024-03-31 | $0 | — | $-451.9K | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842
Your notes
Keep private notes on UEEC — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for UEEC in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns UEEC
Institutional value
$0
Total shares held
6
Distinct holders
1
As of
2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Sarver Vrooman Wealth Advisors | 6 | $0 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
Given the FDA Warning Letter cited modification of FDA correspondence shown to the IRB, what personnel accountability or terminations have occurred?
- 2
With only $250,000 net from Alumni and a $0.06 conversion price, what's your monthly burn and runway through PMA resolution?
- 3
Who is the 'established hemostatic device company' acting as substitute Sponsor, and what economics has UHP conceded for Rights to Reference?
Refreshed when UEEC files a new report · last from 2026-04-15